Day One Biopharmaceuticals shares are trading higher after the company announced the FDA accepted its NDA for tovorafenib in relapsed or progressive pediatric low-grade glioma, granted priority review and assigned a PDUFA date of April 30, 2024.
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for tovorafenib, a treatment for relapsed or progressive pediatric low-grade glioma. The FDA has granted priority review and assigned a Prescription Drug User Fee Act (PDUFA) date of April 30, 2024. This news has led to a rise in the company's share prices.
October 30, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Day One Biopharmaceuticals' shares are trading higher following the FDA's acceptance of its NDA for tovorafenib. The FDA has granted priority review and set a PDUFA date of April 30, 2024.
The FDA's acceptance of Day One Biopharmaceuticals' NDA for tovorafenib, along with the granting of priority review, is a positive development for the company. This news indicates progress in the drug's approval process, which can lead to potential revenue growth in the future. As a result, investor sentiment is likely to be positive, leading to an increase in the company's share price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100